
PYPD
PolyPid Ltd
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.910
Open
3.910
VWAP
3.75
Vol
160.19K
Mkt Cap
38.32M
Low
3.700
Amount
600.03K
EV/EBITDA(TTM)
--
Total Shares
4.80M
EV
35.73M
EV/OCF(TTM)
--
P/S(TTM)
--
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.307
-71.34%
--
--
-0.370
-69.67%
--
--
-0.577
-53.87%
Estimates Revision
The market is revising No Change the revenue expectations for PolyPid Ltd. (PYPD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 36.73%.
EPS Estimates for FY2025
Revise Upward

+2.65%
In Past 3 Month
Stock Price
Go Up

+36.73%
In Past 3 Month
4 Analyst Rating

219.15% Upside
Wall Street analysts forecast PYPD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYPD is 12.00 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy

219.15% Upside
Current: 3.760

Low
9.00
Averages
12.00
High
14.00

219.15% Upside
Current: 3.760

Low
9.00
Averages
12.00
High
14.00
Roth Capital
Buy
downgrade
$12 -> $9
2025-06-19
Reason
Roth Capital
Price Target
$12 -> $9
2025-06-19
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on PolyPid to $9 from $12 and keeps a Buy rating on the shares. The firm is updating its model after the company has executed a new financing agreement that will infuse $27M worth of cash into its coffers, allowing PolyPid to schedule a pre-NDA, New Drug Application, meeting with the FDA in the coming months and potentially file the D-PLEX100 NDA in the first half of 2026, the analyst tells investors in a research note.
Citizens JMP
Outperform
downgrade
$16 -> $14
2025-06-18
Reason
Citizens JMP
Price Target
$16 -> $14
2025-06-18
downgrade
Outperform
Reason
Citizens JMP lowered the firm's price target on PolyPid to $14 from $16 and keeps an Outperform rating on the shares after the company announced that it anticipates gross proceeds of $26.7M from the exercise of 7.6M existing warrants that have been re-priced to a $3.50 exercise price and that it will issue another 7.6M warrants at $4.50. The firm's confidence is bolstered in the potential for D-PLEX100 to get to market following the warrant exercise, the analyst tells investors in a research note.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$12 -> $9
2025-06-18
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$12 -> $9
2025-06-18
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on PolyPid to $9 from $12 primarily due to a higher forecasted share count in Q1 2026, while keeping a Buy rating on the shares. The firm notes PolyPid has executed a new financing agreement that will infuse about $27M worth of cash into its coffers, allowing the company to schedule a pre-NDA meeting with the FDA in the coming months and potentially file the D-PLEX100 NDA in the first half of 2026.
H.C. Wainwright
Brandon Folkes
Buy
upgrade
$11 -> $13
2025-06-09
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$11 -> $13
2025-06-09
upgrade
Buy
Reason
Roth Capital
Boobalan Pachaiyappan
Buy
initiated
$9
2025-06-05
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$9
2025-06-05
initiated
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan initiated coverage of PolyPid with a Buy rating and $9 price target. The firm says its optimism on the shares is driven by D-PLEX100's utility in curbing surgical site infection, particularly in patients undergoing colorectal cancer surgery. The company's current cash position and potential near-term dilution could be balanced by D-PLEX100's new drug application filing in the first half of 2026 and sales potential of over $800M in 2035, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
initiated
$11
2025-06-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$11
2025-06-02
initiated
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for PolyPid Ltd (PYPD.O) is -2.59, compared to its 5-year average forward P/E of -2.26. For a more detailed relative valuation and DCF analysis to assess PolyPid Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.26
Current PE
-2.59
Overvalued PE
-0.46
Undervalued PE
-4.05
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-1.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.60
Undervalued EV/EBITDA
-3.08
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
47.05
Current PS
0.00
Overvalued PS
244.68
Undervalued PS
-150.57
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+20.28%
-7.58M
Operating Profit
FY2025Q1
YoY :
+28.23%
-8.27M
Net Income after Tax
FY2025Q1
YoY :
-48.91%
-0.70
EPS - Diluted
FY2020Q1
-5.16M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PYPD News & Events
Events Timeline
2025-07-15 (ET)
2025-07-15
08:13:31
PolyPid unveils long-acting GLP-1 receptor agonists delivery platform

2025-06-09 (ET)
2025-06-09
07:37:59
PolyPid announces topline results from Phase 3 SHIELD II trial

2025-05-14 (ET)
2025-05-14
07:07:39
PolyPid reports Q1 EPS 70c vs $1.37 last year

Sign Up For More Events
Sign Up For More Events
News
5.0
07-15NewsfilterPolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
6.5
06-21TipRanksAnalysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
4.0
06-18BenzingaRoth Capital Maintains Buy on PolyPid, Lowers Price Target to $9
Sign Up For More News
People Also Watch

RNXT
RenovoRx Inc
1.280
USD
-0.78%

GRCE
Grace Therapeutics, Inc
3.350
USD
-1.18%

PASG
Passage Bio Inc
5.670
USD
+7.59%

FARM
Farmer Bros Co
1.650
USD
+21.32%

RLYB
Rallybio Corp
0.488
USD
+5.62%

AERT
Aeries Technology Inc
0.967
USD
-1.43%

MTEN
Mingteng International Corp Inc
17.730
USD
-16.76%

SPHL
Springview Holdings Ltd
0.525
USD
-2.78%

CENN
Cenntro Inc (The Corporation)
0.615
USD
-5.38%

DALN
Dallasnews Corp
13.670
USD
-0.29%
FAQ

What is PolyPid Ltd (PYPD) stock price today?
The current price of PYPD is 3.76 USD — it has increased 0.27 % in the last trading day.

What is PolyPid Ltd (PYPD)'s business?

What is the price predicton of PYPD Stock?

What is PolyPid Ltd (PYPD)'s revenue for the last quarter?

What is PolyPid Ltd (PYPD)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for PolyPid Ltd (PYPD)'s fundamentals?

How many employees does PolyPid Ltd (PYPD). have?
